IOVA
Iovance Biotherapeutics, Inc.
Biotechnology · Healthcare · United States
8.48
close · 2026-10-30
value
41
cheaper than peers41
quality
69
stronger fundamentals69
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -8.8% | 53 |
| earnings yield, 1 year ago | -15.1% | 51 |
| cash flow yield, 1 year ago | -9.5% | 50 |
| earnings yield, latest year | -12.9% | 49 |
| cash flow yield, 3 years ago | -8.2% | 48 |
| cash flow yield, 2 years ago | -10.0% | 47 |
| price to sales | 13.45× | 45 |
| earnings yield, 2 years ago | -22.3% | 43 |
| earnings yield, 3 years ago | -29.4% | 39 |
| price to book | 5.22× | 34 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 6.6% | 69 |
| revenue growth | 44.8% | 64 |
| operating margin | -113.5% | 55 |
| return on equity | -47.5% | 52 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$149.1M |
| employees | 975 |
| first trade | 2010-10-15 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.09 | -1.28 | -1.89 | -2.49 |
| free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M |
| net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M |
| revenue | $263.5M | $164.1M | $1.2M | $0 |
| unusual items | -$5.1M | $0 | $0 | not reported |